Structural Aspects of Fusion Proteins Determining the Level of Commercial Success

Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

Volumn , Issue , 2013, Pages 39-56

  Somers, Giles ^a  

^a Datamonitor   (United Kingdom)

Author keywords

Decoy receptors; Factors for success; FPs, and cell targets; Fusion proteins; Intellectual property

Indexed keywords

EID: 84886119375     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118354599.ch3     Document Type: Chapter

References (45)

1. Bachmair A, Finley D, Varshavsky A. (1986) In vivo half-life of a protein is a function of its amino-terminal residue. Science 234(4773), 179-186.
2. Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Katre NV. (1988) Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J. Biol. Chem. 263(29), 15064-15070.
3. Roopenian DC, Akilesh S. (2007) FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7(9), 715-725.
4. Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, et al. (2010) Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 115(10), 2057-2064.
5. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, et al. (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature 337(6207), 525-531.
6. Lobo ED, Hansen RJ, Balthasar JP. (2004) Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93(11), 2645-2668.
7. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, McHutchison JG. (2007) Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol. 25(12), 1411-1419.
8. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez- Torres M, Bacon BR, et al. (2010) Albinterferon Alfa-2b was not inferior to PEGylated interferon-a in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 139(4), 1257-1266.
9. Nelson DR, Benhamou Y, ChuangW-L, Lawitz EJ, Rodriguez- Torres M, Flisiak R, et al. (2010) Albinterferon Alfa-2b was not inferior to PEGylated interferon-a in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 139(4), 1267-1276.
10. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, et al. (2008) Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng. Des. Sel. 21(5), 283-288.
11. Bendele A, Seely J, Richey C, Sennello G, Shopp G. (1998) Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci. 42(2), 152-157.
12. Malik DK, Baboota S, Ahuja A, Hasan S, Ali J. (2007) Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv. 4(2), 141-151.
13. Scallon B, Cai A, Solowski N, Rosenberg A, Song X-Y, Shealy D, et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301(2), 418-426.
14. Nestorov I. (2005) Clinical pharmacokinetics of TNF antagonists: howdo they differ? Semin. ArthritisRheum. 34(5 Suppl. 1), 12-18.
15. Gomez-Reino JJ, Carmona L. (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res. Ther. 8(1), R29.
16. Kohno T, Tam L-TT, Stevens SR, Louie JS. (2007) Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J. Investig. Dermatol. Symp. Proc. 12(1), 5-8.
17. Kast RE, Altschuler EL. (2004) Bone density loss in Crohn's disease: role of TNF and potential for prevention by bupropion. Gut 53(7), 1056.
18. Dubost JJ, Soubrier M, Ristori JM, Beaujon G, Oualid T, Bussiere JL, et al. (1997) An open study of the anti-TNF alpha agent pentoxifylline in the treatment of rheumatoid arthritis. Rev. Rhum. Engl. Ed. 64(12), 789-793.
19. Qin C, Ding Y, Huang D, Xu J, Ma R, Huang J. (2011) Downregulation of TNF-alpha by small interfering RNA inhibits particle- induced inflammation in vitro. Artif. Organs 35(7), 706-714.
20. Deng G-M. (2007) Tumor necrosis factor receptor pre-ligand assembly domain is an important therapeutic target in inflammatory arthritis. BioDrugs 21(1), 23-29.
21. Lansigan F, Stearns DM, Foss F. (2010) Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag. Res. 2, 53-59.
22. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. (2002) Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 99(7), 2310-2314.
23. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, et al. (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug. Chem. 21(1), 84-92.
24. Heisler I, Keller J, Tauber R, Sutherland M, Fuchs H. (2003) A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins. Int. J. Cancer 103(2), 277-282.
25. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. (2000) Highdose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6(Suppl. 1), S11-14.
26. Rizzardi G, Traversari C, Valentinis B, Di Matteo P, Alberici L, Cota M, et al. (2010) Contribution of NGR and TNF portions of NGR-TNF to tumor vessel-specific homing and apoptosis in vivo. ASCO Meeting Abstracts 28(15 suppl.), e13554.
27. Arap W, Pasqualini R, Ruoslahti E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349), 377-380.
28. Silverman J, Liu Q, Lu Q, Bakker A, To W, Duguay A, et al. (2005) Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat. Biotechnol. 23(12), 1556-1561.
29. Nickerson-Nutter C, Tchistiakova L, Seth NP, Kasaian M, Sibley B, Olland S, et al. (2011) Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys. Rheumatology (Oxford) 50(6), 1033-1044.
30. Jain RK. (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50(3 Suppl.), 814s-819s.
31. Prior CP, Sadeghi H, Turner A. (2011) Oral delivery of modified transferrin fusion proteins. US 2011/0091543 A1. US.
32. Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML. (2000) Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J. Immunol. 165(9), 5112-5121.
33. Corti A, Curnis F, Arap W, Pasqualini R. (2008) The neovasculature homing motif NGR: more than meets the eye. Blood 112(7), 2628-2635.
34. Michael NP, Chester KA, Melton RG, Robson L, Nicholas W, Boden JA, et al. (1996) In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein. Immunotechnology 2(1), 47-57.
35. Bhatia J, Sharma SK, Chester KA, Pedley RB, Boden RW, Read DA, et al. (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int. J. Cancer 85(4), 571-577.
36. Orita I, Sakamoto N, Kato N, Yurimoto H, Sakai Y. (2007) Bifunctional enzyme fusion of 3-hexulose-6-phosphate synthase and 6-phospho-3-hexuloisomerase. Appl. Microbiol. Biotechnol. 76(2), 439-445.
37. Tamada Y, Swanson BA, Arabshahi A, Frey PA. (1994) Preparation and characterization of a bifunctional fusion enzyme composed of UDP-galactose 4-epimerase and galactose- 1-P uridylyltransferase. Bioconjug. Chem. 5(6), 660-665.
38. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, et al. (2010) Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363(4), 355-364.
39. Zhou Q-H, Sumbria R, Hui EK-W, Lu JZ, Boado RJ, Pardridge WM. (2011) Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. J. Pharmacol. Exp. Ther. 339(2), 618-623.
40. Jain A, Chasoo G, Singh SK, Saxena AK, Jain SK. (2011) Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisation. J Microencapsul. 28(1), 21-28.
41. Chu L, Robinson DK. (2001) Industrial choices for protein production by large-scale cell culture. Curr. Opin. Biotechnol. 12(2), 180-187.
42. GlaesnerW, Millican J, Vick AM. (2009) GLP-1 analog fusion proteins. US 2009/0074769 A1. US.
43. Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, et al. (2010) Fc-glycosylation influences Fc g receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J. Immunol. 185(11), 6876-6882.
44. Ghirlando R, Lund J, Goodall M, Jefferis R. (1999) Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Immunol. Lett. 68(1), 47-52.
45. Beasley D. (2011) FDA to issue biosimilar guidance in 2011. Reuters 9. May.